|
- ADSTILADRIN® (nadofaragene firadenovec-vncg) | For HCP
ADSTILADRIN® is the first and only FDA-approved intravesical gene therapy for patients with high-risk BCG-unresponsive NMIBC See Important Safety Info
- Adstiladrin: Uses, Dosage, Side Effects Warnings - Drugs. com
Adstiladrin (nadofaragene firadenovec-vncg) is a gene therapy used to treat high-risk Bacillus CalmetteGuérin (BCG)-unresponsive non-muscle invasive bladder cancer Includes Adstiladrin side effects, interactions and indications
- Package Insert - ADSTILADRIN
ADSTILADRIN is a non-replicating adenoviral vector-based gene therapy indicated for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive
- Nadofaragene firadenovec - Wikipedia
Nadofaragene firadenovec, sold under the brand name Adstiladrin, is a gene therapy for the treatment of bladder cancer [1][3][4] It is a non-replicating (cannot multiply in human cells) adenoviral vector-based gene therapy
- More about ADSTILADRIN® – Bladder Cancer Advocacy Network
What is ADSTILADRIN? ADSTILADRIN (nadofaragene firadenovec-vncg) was approved in the United States in 2022 and is fully available for appropriate patients as a treatment that may help people live better lives on their bladder cancer journey ADSTILADRIN is a localized gene therapy designed to help the immune system fight NMIBC directly within the bladder Administered […]
- Package Insert - ADSTILADRIN
ADSTILADRIN is a non-replicating adenoviral vector-based gene therapy indicated for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors (1)
- ADSTILADRIN- nadofaragene firadenovec-vncg suspension - DailyMed
ADSTILADRIN (nadofaragene firadenovec-vncg) is a non-replicating adenoviral vector-based gene therapy for intravesical instillation It is a recombinant adenovirus serotype 5 vector containing a
- HOW TO USE ADSTILADRIN
Retain ADSTILADRIN in the bladder for 1 hour after administration During the 1-hour dwell time, the patient should be repositioned approximately every 15 minutes from left to right and back to abdomen to maximize bladder surface exposure
|
|
|